January 10, 2023
Clarivate Identifies Fifteen Potential Blockbuster Drugs in Annual Drugs to Watch Report. Clarivate announced the release of its annual Drugs to Watch report. In its 10th year, the Drugs to Watch report provides in-depth predictive analysis of drugs with the potential to transform treatment paradigms and serve unmet patient needs. The report serves as a key industry resource in an ever-evolving drug innovation landscape - with more than 70 drugs having been identified as Drugs to Watch. This year's analysis identifies drugs entering the market or launching key indications in 2023 which are predicted to achieve blockbuster status by 2027 or be clinical game changers for millions of patients worldwide. Clarivate analysts identified 15 late-stage experimental treatments that are each forecast to deliver annual sales of more than $1 billion within five years. These promising advancements include a broad spectrum of therapeutic developments for rare diseases and tough-to-treat conditions, including HIV, Parkinson's disease, Crohn's disease, alopecia, multiple myeloma and breast cancer. [Full Announcement].
January 5, 2023
Tabita Andersson has been promoted to Senior Vice President, Communications & Brand. Tabita Andersson joined Clarivate in April 2019 and was appointed Senior Vice President, Communications & Brand in January 2023. In this role, she focuses on continually strengthening the company's reputation and growing the brand globally. [Full Announcement].
January 3, 2023
Clarivate and the Chinese Academy of Sciences release annual joint report to identify 165 research fronts. In the report, "Research Fronts" are defined when scientists undertake the fundamental scholarly act of citing one another's work, reflecting a specific commonality in their research sometimes experimental data, or a method, a concept or hypothesis. Research Fronts are discovered by tracking the world's most significant scientific and scholarly literature and the patterns and groupings of how papers are cited in particular, clusters of papers that are frequently cited together over a five-year period. A Research Front is then formed when such a group of highly cited papers attains a certain level of activity and coherence. For the report, experts used the Clarivate Essential Science Indicators (ESI) database which is built on the foundation of the Web of Science index, to conduct co-citation analysis. The 2022 report starts with 12,610 Research Fronts in the ESI from 2016 to 2021 and aims to discover which Research Fronts were most active or developing most rapidly. [Full Announcement].
December 22, 2022
A Letter to Shareholders from Jonathan Gear, Clarivate CEO. After much work and planning, in the third quarter of 2022 we began reporting our financial results externally based on three segments: Academia & Government (A&G), Life Sciences & Healthcare (LS&H) and Intellectual Property (IP). This is an intuitive way to look at our business and reflects our core customer end-markets. It is how I see the business naturally operating and aligning. Each segment will be led by a respective President. A search for the roles is underway, evaluating both external and internal candidates. I expect this to take a few months. In the meantime, our executive team is taking an active role in managing the segments with me. [Full Announcement].
Clarivate adopts tax benefits preservation plan to protect availability of net operating losses. Clarivate announced that its Board of Directors adopted a tax benefits preservation plan designed to protect the availability of Clarivate's U.S. net operating loss carryforwards and certain other U.S. tax attributes, which can be utilized in certain circumstances to offset future U.S. tax liabilities. As of September 30, 2022, Clarivate estimates that it had U.S. federal net operating loss and interest carryforwards in excess of $1.0 billion. [Full Announcement].
December 21, 2022
Clarivate reduces board size, enhancing corporate governance. Clarivate announced that, to further enhance the Company's governance profile, it has decreased the size of its Board of Directors from 14 to 11 members. Three directors, Balakrishnan S. Iyer, Kosty Gilis and Roxane White, have voluntarily agreed to resign, effective immediately. Following these changes to the Board, 10 of its 11 directors are independent and 5 of its members, or 45%, are female or racially diverse. [Full Announcement].
December 6, 2022
Clarivate expands real world data and analytics solutions with addition of U.S. Specialty Pharmacy Data. Clarivate announced the inclusion of linked specialty pharmacy claims data within real world data solutions. The new U.S. dataset will expand the real world data and analytics offerings from Clarivate. Researchers can access an in-depth view of high-cost medications and valuable insights into the patient's treatment journey in chronic, complex and rare diseases, such as rheumatoid arthritis, inflammatory conditions, and cancer. [Full Announcement].
November 30, 2022
BlueDot and Clarivate partner to strengthen the resilience of organizations, through heightened disease intelligence. BlueDot, a global leader in infections disease intelligence, announced its partnership with Clarivate, a global leader in providing trusted information and insights to accelerate the pace of innovation. Now, customers of Clarivate can access BlueDot's innovative technology rooted in artificial intelligence and machine-learning to support in making educated, time-sensitive decisions in the face of biothreats. Through Clarivate, organizations can access BlueDot's infectious disease alerts and risk assessments, in addition to a wide variety of datasets, analysis, and modelling. [Full Announcement].
November 17, 2022
Clarivate Annual G20 Scorecard Report Reveals Insights into World's Leading Research Economies. Clarivate launched its annual report which examines the research performance of each of the members of the G20 with a visual comparative snapshot for each. The report, The Annual G20 Scorecard Research Performance 2022, has been created by the Institute for Scientific Information at Clarivate to coincide with this year's G20 Summit hosted by Bali. It includes both a written summary and an array of graphs and exhibits that highlight the research performance of Argentina, Australia, Brazil, Canada, Mainland China, France, Germany, India, Indonesia, Italy, Japan, Mexico, Russia, Saudi Arabia, South Africa, South Korea, Turkey, the United Kingdom and the United States. [Full Announcement].
November 16, 2022
Clarivate Partners with IPwe to Enhance AI and Blockchain Patent Solutions. Clarivate announced a strategic partnership with IPwe Inc., a leader in blockchain technology that provides smart solutions for the management of intangible assets through data-driven recommendations. The vision of this partnership is to enable Clarivate and IPwe customers to accelerate innovation through accessing uniquely curated patent data from Clarivate within IPwe's artificial intelligence, predictive analytics, and blockchain technology platform. [Full Announcement].
November 15, 2022
Clarivate names world's influential researchers with Highly Cited Researchers 2022 list. Clarivate revealed its 2022 list of Highly Cited Researchers: individuals at universities, research institutes and commercial organizations who have demonstrated a disproportionate level of significant and broad influence in their field or fields of research. The methodology draws on data from the Web of Science citation index, together with analysis performed by bibliometric experts and data scientists at the Institute for Scientific Information at Clarivate. ISI analysts have awarded Highly Cited Researcher 2022 designations to 6,938 researchers from across the globe who demonstrated significant influence in their chosen field or fields over the last decade. The list is truly global, spanning 69 countries or regions and spread across a diverse range of research fields in the sciences and social sciences. [Full Announcement].
November 8, 2022
Clarivate declares dividend on mandatory convertible preferred shares. Clarivate announced that its board of directors declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares, payable in cash on December 1, 2022 to shareholders of record at the close of business on November 15, 2022. [Full Announcement].
Clarivate reports Third Quarter 2022 results. Clarivate reported results for the third quarter ended September 30, 2022. Revenues of $635.7 million increased 8%, and 50.9% at constant currency driven primarily by the acquisition of ProQuest. Organic revenues(1) increased 2% as increases in subscription revenues of 4.3% and re-occurring revenues of 2.4% were partially offset by a decline in transactional revenues of 9.4%. Net loss attributable to ordinary shares was $4,434.4 million compared to net income attributable to ordinary shares of $6.0 million in the prior year quarter due to the $4,448.6 million non-cash impairment of goodwill; Net loss per diluted share of $6.64 increased by $6.52 due to the non-cash impairment of goodwill. Adjusted Net Income(1) of $143.7 million increased 5%; Adjusted Income per diluted share(1) of $0.20 increased 25.0% or $0.04. Adjusted EBITDA(1) of $271.6 million increased 9% driven by earnings contributions from acquisitions, organic growth and cost savings from integration programs; Adjusted EBITDA Margin(1) of 42.7% decreased 30 basis points. [Full Announcement].
November 7, 2022
Clarivate and OCLC Settle Lawsuit. Clarivate announced that it has signed a settlement agreement and release with OCLC. Clarivate continues to deny OCLCs allegations of wrong-doing and maintains that the issue lay between OCLC and its customers, who sought to co-create an efficient community platform for sharing of bibliographic records. Clarivate will not develop a record exchange system of MARC records that include records which OCLC has claimed are subject to its policy and contractual limitations. Clarivate will bear its own fees and costs. [Full Announcement].
November 1, 2022
Clarivate successfully completes divestiture of MarkMonitor to Newfold Digital. Clarivate announced that it has completed the divestiture of MarkMonitor, an industry-leading enterprise-level provider of domain management solutions, to Newfold Digital, a leading web and commerce technology provider backed by affiliates of Clearlake Capital Group, L.P. and Siris Capital Group, LLC. Previously, Clarivate announced on September 12, 2022, its intent to divest MarkMonitor to Newfold. [Full Announcement].
October 26, 2022
Clarivate identifies the role of research and innovation in the world's shift to sustainable energy. Clarivate, a global leader in providing trusted information and insights to accelerate the pace of innovation, released a new report, A study of energy in transition: the role of research and innovation in the world's shift to sustainable energy sources. It finds that innovation activity in the sustainable energy space is tailing off, as research and inventive activities for respective renewable develops at different paces. This finding is based on Clarivate data normalized for overall increases in scientific journal and patent output increases globally in all subject areas. [Full Announcement].
September 23, 2022
Clarivate Supports Peer Review Week by Raising the Profile of Peer Reviewers. Clarivate celebrates Peer Review Week with the announcement of new services for authors to better track their peer review activity. This includes academic publications, citation metrics and journal editing, now all in one place within the newly launched Web of Science Researcher Profiles. Clarivate recently launched the next generation of Web of Science Researcher Profiles to incorporate the best features of Publons and ResearcherID, creating a one-stop destination for researchers to manage their academic profile and demonstrate their expertise, including in peer review. [Full Announcement].
September 21, 2022
Clarivate reveals Citation Laureates 2022: Annual List of Researchers of Nobel Class. Clarivate named 20 world-class researchers from four countries as Citation Laureates. These are researchers whose work is deemed to be of Nobel class', as demonstrated by analysis carried out by the Institute for Scientific Information, part of Clarivate. [Full Announcement].
September 13, 2022
Newfold Digital signs agreement to acquire MarkMonitor from Clarivate. Clarivate announced that Newfold Digital, a leading web and commerce technology provider backed by Clearlake Capital Group and Siris Capital Group,, has signed a definitive agreement to purchase MarkMonitor, an industry-leading enterprise-level provider of domain management solutions. Under the terms of the agreement, Clarivate will receive cash proceeds of approximately $302.5 million. The transaction is expected to close in late 2022 subject to the satisfaction of regulatory approvals and other customary closing conditions. [Full Announcement].
September 7, 2022
Clarivate announces winner of the 2022 Eugene Garfield Award for Innovation in Citation Analysis. Clarivate has awarded the Eugene Garfield Award for Innovation in Citation Analysis to the late Dr. Saeed Ul Hassan, senior lecturer in AI/Data Science at Manchester Metropolitan University. The award was announced at the 26th International Conference on Science, Technology and Innovation Indicators (STI 2022) by Dr. Gali Halevi, Director of the Institute for Scientific Information at Clarivate. [Full Announcement].